HIGHLIGHTS
- who: J Nepal Med Assoc et al. from the Department of Medical Microbiology, Shi-Gan International College of Science and Technology, Maharajgunj have published the research work: JNMA I VOL 60 ISSUE 252 August, in the Journal: (JOURNAL) of 11/06/2021
- what: In this of three patients with severe COVID-19 the authors focus on the rationale for utilization of tocilizumab an anti-interleukin-6 receptor antibody which could block the signal transduction pathway of interleukin-6.
SUMMARY
CASE REPORTS Routine laboratory tests showed elevated levels of C-reactive protein . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.